Pharmaceutical preparations in the nature of gammaglobulin preparations for use in the treatment of primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplant in adults, chronic B-cell lymphocytic leukemia, pediatric HIV infection, chronic inflammatory demyelinating polyneuropathy, post-transfusion purpura, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneurophathy, anemia because of parvovirus B19, patients with stable multiple myeloma who are at high risk for recurrent infection, cytomegalovirus (CMV)-negative recipients of CMV-positive organs, hypogammaglobulinemic neonates with risk factor for infection or morbidity, intractable epilepsy, systemic vasculitic syndromes, warm-type automimmune hemolytic anemia, neonatal alloimmune thrombocytopenia when unresponsive to other treatments, immune-mediated neutropenia, decompensation in myasthenia gravis, dermatomyositis, polymyosits, thrombocytopenia when severe and unresponsive to other treatments